Please see the latest VisiRose, Inc. presentation for any and all footnotes as well as disclosure items.
The information on this website may include ”forward-looking statements” within the meaning of U.S. federal securities legislation and relating to the business of VisiRose, Inc. (VisiRose or the Company), its partners, and its affiliates that are based on the opinions and estimates of Company management and are subject to a variety of risks, uncertainties, and other factors, which could cause actual events or results to differ materially from those projected in these forward-looking statements. Forward-looking statements are often, but not always, identified using words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of drug agents and candidates and/or therapeutic uses under investigation by the Company have not been established. There is no guarantee these agents, candidates, and/or uses will receive health authority approval or become commercially available in any country or such candidates as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on them.
Forward-looking statements contained in this presentation are made as of the date hereof or as of the date specifically specified herein. The Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable federal securities laws. Forward-looking statements are expressly qualified by this cautionary statement.